Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown
New York
10591
U.S.A.
Phone:
914-847-7400
Fax:
n/a
|
If you are looking for an uncommon opportunity -- a chance to join an organization known for its scientific excellence in the research and development of pharmaceuticals -- it's time to consider Regeneron.
Founded on the principle that strong science would lead to important new medicines, Regeneron has become an integrated biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Regeneron currently markets ARCALYST (R) (rilonacept) Injection for Subcutaneous Use and EYLEA (TM) (aflibercept) Injection. Regeneron has therapeutic candidates in Phase 3 clinical trials for the prevention of gout flares, central retinal vein occlusion, diabetic macular edema, certain cancers, and rheumatoid arthritis. Additional therapeutic candidates are in earlier stage development programs in cholesterol reduction, allergic conditions, pain, and cancer.
Visit our website – www.regeneron.com
Check out our openings – www.regeneron.jobs
Email:
Ownership:
Public
Web Site:
Regeneron Pharmaceuticals, Inc.
Employees:
1800
Symbol: REGN
|